Side Effects of Hormone Replacement Therapy in Women
Hormone replacement therapy carries well-documented serious risks including increased breast cancer, stroke, venous thromboembolism, coronary heart disease, and gallbladder disease, with the magnitude and timing of these harms varying by formulation and duration of use. 1, 2, 1
Major Cardiovascular and Thromboembolic Risks
The most concerning side effects involve cardiovascular and thromboembolic events:
- Stroke: 8-11 additional cases per 10,000 woman-years (occurs with both estrogen-progestin and estrogen-only therapy) 1
- Venous thromboembolism:
- Coronary heart disease: 7 additional CHD events per 10,000 woman-years (primarily with estrogen-progestin) 1, 2
Critical timing consideration: Risks for venous thromboembolism, CHD, and stroke are highest within the first 1-2 years of therapy 1. This early risk window is particularly important for clinical decision-making.
Cancer Risks
Breast Cancer
- 8 additional invasive breast cancers per 10,000 woman-years with estrogen-progestin therapy 1
- Risk increases with longer-term use (appears to increase progressively with duration beyond 1-2 years) 1
- Paradoxically, estrogen-only therapy may slightly reduce breast cancer risk in women with hysterectomy 4, 3
Endometrial Cancer
- Unopposed estrogen dramatically increases endometrial cancer risk in women with intact uterus 1
- This risk is largely eliminated when progestin is added for more than 10 days per cycle 5
Lung Cancer
- While incidence may not increase, death from lung cancer increases (5 additional deaths per 10,000 woman-years with estrogen-progestin) 4, 3
Colorectal Cancer
Other Significant Harms
- Gallbladder disease/cholecystitis: 20-33 additional cases per 10,000 woman-years (higher with estrogen-only) 1, 3
- Probable dementia: 22 additional cases per 10,000 woman-years (in women initiating therapy after age 65) 4, 3
- Urinary incontinence: 872-1,271 additional cases per 10,000 woman-years (substantial increase) 3
Common but Less Serious Side Effects
Based on real-world data, 43% of women report side effects, with many experiencing multiple symptoms 6:
- Weight gain: Most frequently reported (56.3% of those with side effects), though not definitively proven to be HRT-related 6
- Side effects constitute the major reason for discontinuation in over half of women who stop therapy 6
Critical Risk Modifiers
Age and Time Since Menopause
The benefit-risk ratio fundamentally changes based on timing:
- Favorable ratio: Women <60 years old OR within 10 years of menopause onset 7
- Unfavorable ratio: Women >60 years old OR >10 years from menopause onset have greater absolute risks of CHD, stroke, thromboembolism, and dementia 1, 2, 7
Formulation Differences
- Estrogen-progestin (combined therapy): Higher risks for breast cancer, CHD, and lung cancer mortality
- Estrogen-only: Lower breast cancer risk but still carries stroke, thromboembolism, and gallbladder disease risks 1, 3
Common Pitfalls to Avoid
Don't prescribe HRT for chronic disease prevention - The USPSTF explicitly recommends against routine use for preventing osteoporosis, heart disease, or other chronic conditions (Grade D recommendation) 2
Don't initiate therapy in older women - Starting HRT in women >60 or >10 years post-menopause substantially increases absolute risk without proportional benefit 1, 7
Don't forget progestin protection - Women with intact uterus require progestin or bazedoxifene to prevent endometrial cancer 8, 5
Don't ignore individual risk factors - Women with factor V Leiden, obesity, prior thromboembolism, or cardiovascular risk factors face amplified risks 3
Evidence Quality Note
These recommendations are based primarily on high-quality randomized controlled trial data from the Women's Health Initiative (WHI), the largest and most rigorous studies of HRT 1, 2, 1, 3. The evidence for estrogen-progestin is stronger (fair to good) than for estrogen-only, which relies more on observational data 1.
When HRT is used for menopausal symptom relief (not chronic disease prevention), use the lowest effective dose for the shortest possible time, with periodic reevaluation of continued need 1, 2, 1, 7.